Literature DB >> 10424429

Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein.

A A Chepurnov1, M N Tuzova, V A Ternovoy, I V Chernukhin.   

Abstract

Ebola virus (EV), an extremely infectious pathogen, causes severe hemorrhagic fever in humans and nonhuman primates. The disease pattern includes damage of parenchymal cells of vital organs in association with hemostatic and immune disorders. Vaccination with the inactivated virions does not provide an effective immune protection against the disease. The inadequate immune response may be directly caused by the virus, and, hence, it may presumably be crucial in the pathogenic process and prophylactic treatment of Ebola infection. The suggested immunosuppressive properties of EV were examined in this study. We have demonstrated that the whole heat-inactivated virions can dose-dependently suppress human lymphocyte mitogen-stimulated proliferation in vitro. In further analyses, we identified the viral protein responsible for the suppressive effect, and we showed that it was provided by a protein corresponding to a 125-kDa envelope glycoprotein (GP-125). The protein alone inhibited lymphocyte proliferation, whereas the other viral proteins were without significant effect on blastogenesis. To determine the immunosuppressive properties of different portions of GP-125, deletion mutants of GP were designed based on predicted localisation of antigen sites. They were expressed as recombinant proteins and studied in proliferation assays. We identified a 40-amino acid sequence at the N-terminus of GP-125 that exerted a suppressive effect on blastogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424429     DOI: 10.1016/s0165-2478(99)00058-9

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Sorting of Marburg virus surface protein and virus release take place at opposite surfaces of infected polarized epithelial cells.

Authors:  C Sänger; E Mühlberger; E Ryabchikova; L Kolesnikova; H D Klenk; S Becker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

3.  Covalent modifications of the ebola virus glycoprotein.

Authors:  Scott A Jeffers; David Avram Sanders; Anthony Sanchez
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 4.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

Review 5.  Camouflage and misdirection: the full-on assault of ebola virus disease.

Authors:  John Misasi; Nancy J Sullivan
Journal:  Cell       Date:  2014-10-16       Impact factor: 41.582

6.  Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.

Authors:  Anthony Sanchez; Matthew Lukwiya; Daniel Bausch; Siddhartha Mahanty; Angela J Sanchez; Kent D Wagoner; Pierre E Rollin
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

Review 7.  Updates in diagnosis and management of Ebola hemorrhagic fever.

Authors:  Salah Mohamed El Sayed; Ali A Abdelrahman; Hani Adnan Ozbak; Hassan Abdullah Hemeg; Ali Mohammed Kheyami; Nasser Rezk; Mohamed Baioumy El-Ghoul; Manal Mohamed Helmy Nabo; Yasser Mohamed Fathy
Journal:  J Res Med Sci       Date:  2016-10-18       Impact factor: 1.852

8.  Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.

Authors:  A A Chepurnov; E I Kazachinskaya; E A Kazachkova; K A Sharshov; Yu V Kononova; A A Shelemba; A Yu Alekseev; M A Gulyeva; M I Voevoda; A M Shestopalov
Journal:  Bull Exp Biol Med       Date:  2021-11-17       Impact factor: 0.804

9.  Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection.

Authors:  Jeffrey R Kugelman; Michael S Lee; Cynthia A Rossi; Sarah E McCarthy; Sheli R Radoshitzky; John M Dye; Lisa E Hensley; Anna Honko; Jens H Kuhn; Peter B Jahrling; Travis K Warren; Chris A Whitehouse; Sina Bavari; Gustavo Palacios
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.